Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...
Tallennettuna:
Päätekijät: | , , , , , , , , , , |
---|---|
Aineistotyyppi: | Kirja |
Julkaistu: |
BioExcel Publishing Ltd,
2016-12-01T00:00:00Z.
|
Aiheet: | |
Linkit: | Connect to this object online. |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
Hyllypaikka: |
A1234.567 |
---|---|
Nide 1 | Saatavissa |